Interest in the microbiome continues to grow at a robust rate, underlying its potential to significantly benefit human health. In part 1 of this series, the role of the microbiome in impacting experimental reproducibility and translatability was examined. In part 2, Dr. Alexander Maue at Taconic Biosciences focuses on the microbiome’s ability to alter the effectiveness of therapeutics by transforming drugs into bioactive or inactive forms, and how the presence or absence of specific microbes is associated with clinical outcomes.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2020/07/Betting-on-the-Bug-Part-III_Leveraging-the-Microbiome.pdf”]